Advanced Heart Failure Epidemiology Forecast 2025-2034

Advanced heart failure is the final stage (Stage D) of heart failure that occurs when the heart's capacity to pump blood is significantly impaired even with the best medical care. It is typified by enduring symptoms that greatly interfere with day-to-day functioning and frequently call for specific interventions, such as exhaustion, fluid retention, and dyspnea. According to American Heart Association Journal, the risk of developing advanced heart failure varies by patient characteristics. Advanced heart failure epidemiology forecast suggests that patients who are older, male, have diabetes, chronic lung disease, lower blood sodium level, vascular disease, and higher estimated heart pressures are at higher risk of developing advanced heart failure.

Advanced Heart Failure Epidemiology Forecast Report Coverage

Expert Market Research's “Advanced Heart Failure Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of advanced heart failure. It projects the future incidence and prevalence rates of advanced heart failure cases across various populations. The study covers age and type as major determinants of the advanced heart failure population. The report highlights patterns in the prevalence of advanced heart failure over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of advanced heart failure in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Advanced Heart Failure Understanding: Disease Overview

The last stage (Stage D) of heart failure occurs when the heart's function is significantly impaired even with the best medical care. The stage results in frequent hospitalizations, exhaustion, fluid retention, and chronic dyspnea. The causes of advanced heart failure include cardiomyopathy, hypertension, and coronary artery disease. Right cardiac catheterization, BNP measurements, and echocardiography are used in the diagnosis process.

Advanced Heart Failure Epidemiology Perspective

Advanced heart failure epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for advanced heart failure by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for advanced heart failure and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• According to the Journal of Cardiac Failure, approximately 6.7 million Americans over 20 years of age have heart failure, and the prevalence is expected to rise to 8.7 million Americans in 2030, 10.3 million in 2040, and 11.4 million Americans by 2050. Studies suggest that approximately 10% of patients are having advanced heart failure.
• Research studies shows that in Europe, heart failure affects over 15 million people, with a prevalence of about 17 cases per 1000 people. This number is expected to increase in the coming years.
• According to JMA Journal, in Japan, the number of patients who will newly develop heart failure in 2025 is estimated to reach 370,000.

Country-wise Advanced Heart Failure Epidemiology

Advanced heart failure epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Advanced heart failure (AHF) epidemiology varies globally due to differences in healthcare access, disease prevalence, and risk factors. According to an article published by the National Health Institute, heart failure has a prevalence of 1.44% in the UK.

Advanced Heart Failure: Treatment Overview

The treatment for the disease includes implantable devices (ICD, CRT), sophisticated therapies like LVAD or cardiac transplantation, and guideline-directed medical therapy (GDMT). Patients who are not eligible for modern therapies can benefit from palliative care by having their symptoms reduced. The treatment is intended to improve survival and manage symptoms. For fluid control, ACE inhibitors, beta-blockers, aldosterone antagonists, SGLT2 inhibitors, and diuretics are all part of guideline-directed medical therapy (GDMT). Cardiac resynchronization therapy (CRT) enhances heart function, whereas implanted cardioverter defibrillators (ICD) prevent sudden death. In extreme situations, left ventricular assist devices (LVADs) help maintain circulation and are frequently used as a stopgap measure before heart transplantation. Heart transplantation is still the only effective treatment for qualified patients. In order to ensure comfort and quality of life for patients with end-stage disease, palliative care is crucial for symptom reduction in those who are not suitable for advanced therapies.

Key Questions Answered

• What are the key findings of advanced heart failure epidemiology in the 8 major markets?
• What will be the total number of patients with advanced heart failure across the 8 major markets during the forecast period?
• What was the country-wise prevalence of advanced heart failure in the 8 major markets in the historical period?
• Which country will have the highest number of advanced heart failure patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of advanced heart failure during the forecast period of 2025-2034?
• What are the currently available treatments for advanced heart failure?
• What are the disease risks, signs, symptoms, and unmet needs of advanced heart failure?

Related Reports

Congestive Heart Failure (CHF) Epidemiology Forecast

Chronic Heart Failure Pipeline Analysis Report